CRONNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Cronos Group Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.25+0.04 (+1.25%)
Close on Oct 19, 2026
- Market cap
- $1.22B
- P/E (TTM)
- 16.3
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
42.8%+98.1 pts over 5 years
Operating margin
-11.9%+457.7 pts over 5 years
Net margin
-6.4%+150.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +24.6% | +19.1% | +25.7% | – | |
| Gross profit | +149.1% | +59.6% | – | – | |
| Free cash flow | -97.7% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -4.2% | -0.9% | |
| Return on assets | – | -3.6% | -0.8% | |
| Current ratio | – | 6.63 | 19.59 | |
| Interest coverage | – | -1179.5× | – | |
| Inventory turnover | – | 1.8× | 2.1× | |
| Capex to revenue | – | 67.2% | 17.5% | |
| Diluted shares | 78M | 352M | 383M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cronos generated $330.11M from operations and spent $64.97M on capital expenditure, dividends and share buybacks. 85% of that went back into the business.
Generated
$330.11M
Used
$64.97M
Capital expenditure$55.23M85%Dividends$00%Share buybacks$9.74M15%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-6.4%
×Asset turnover0.12×
×Equity multiplier1.10×
=Return on equity, FY2025-0.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -6.4% | 0.12× | 1.10× | -0.9% |
| FY2024 | 34.9% | 0.10× | 1.07× | 3.8% |
| FY2023 | -84.8% | 0.07× | 1.05× | -6.6% |
| FY2022 | -194.5% | 0.07× | 1.05× | -13.6% |
| FY2021 | -613.5% | 0.04× | 1.09× | -26.0% |
| FY2020 | -156.5% | 0.02× | 1.16× | -4.2% |
| FY2019 | 4911.6% | 0.02× | 1.20× | 122.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$9.45M
- Cash generatingOperating cash flow above zero$25.87M
- Return on assets improvedROA up on the prior year3.6% → -0.8%
- Earnings backed by cashOperating cash flow above net income$25.87M vs -$9.45M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose18.84 → 19.59
- No dilutionShare count did not rise386M → 383M
- Gross margin improvedGross margin up on the prior year21.42% → 42.81%
- More efficientAsset turnover rose0.10 → 0.13